Processa Pharmaceuticals, Inc. Common (PCSA) Stock Price

PCSAStock

$2.18−60.18%52W

Market Cap$6.09M

P/E—

PEG Ratio—

Div yield—

Beta1.24

PCSA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-17.31%

Price vs S&P 500 (4W)-31.90%

VGM Score28.69

Book Value / Share (Quarterly)$0.95

P/TBV (Annual)2.35x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-4.57

Price vs S&P 500 (YTD)-36.61%

Gross Margin (TTM)32.24%

Net Profit Margin (TTM)-2981.25%

EPS (TTM)$-10.90

10-Day Avg Trading Volume0.05M

EPS Excl Extra (TTM)$-10.90

EPS (Annual)$-10.36

ROI (Annual)-243.20%

Gross Margin (Annual)100.00%

Net Profit Margin (5Y Avg)-3230.38%

Cash / Share (Quarterly)$0.63

ROA (Last FY)-173.59%

EBITD / Share (TTM)$-7.82

ROE (5Y Avg)-315.34%

Operating Margin (TTM)-2707.69%

Cash Flow / Share (Annual)$-4.43

P/B Ratio2.74x

P/B Ratio (Quarterly)2.64x

Net Income / Employee (Annual)$-1,130,300

EV / Revenue (TTM)63.28x

Net Interest Coverage (TTM)-54.45x

ROA (TTM)-200.80%

EPS Incl Extra (Annual)$-10.36

Current Ratio (Annual)2.54x

Quick Ratio (Quarterly)0.85x

3-Month Avg Trading Volume0.19M

52-Week Price Return-60.18%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$9.32

P/S Ratio (Annual)1391.21x

Asset Turnover (Annual)1.67x

52-Week High$14.24

Operating Margin (5Y Avg)-1796.65%

EPS Excl Extra (Annual)$-10.36

Tangible BV CAGR (5Y)82.09%

26-Week Price Return-6.06%

Quick Ratio (Annual)2.48x

13-Week Price Return-15.40%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)0.98x

Enterprise Value$5.26M

Asset Turnover (TTM)0.18x

Book Value / Share Growth (5Y)-41.76%

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)1.15x

Pretax Margin (Annual)-6744.00%

Cash / Share (Annual)$2.15

3-Month Return Std Dev128.49%

Gross Margin (5Y Avg)39.43%

Net Income / Employee (TTM)$-1,175,600

ROE (Last FY)-243.20%

Net Interest Coverage (Annual)-72.46x

EPS Basic Excl Extra (Annual)$-10.36

Receivables Turnover (TTM)227.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-10.90

Receivables Turnover (Annual)226.80x

ROI (TTM)-281.25%

P/S Ratio (TTM)86.20x

Pretax Margin (5Y Avg)-3012.80%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$9.32

Price vs S&P 500 (52W)-78.49%

Year-to-Date Return-24.65%

5-Day Price Return3.33%

EPS Normalized (Annual)$-10.36

ROA (5Y Avg)-218.81%

Net Profit Margin (Annual)-6720.00%

Month-to-Date Return0.93%

Cash Flow / Share (TTM)$-0.81

EBITD / Share (Annual)$-10.68

Operating Margin (Annual)-1336.00%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-314.79%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-10.90

P/TBV (Quarterly)2.35x

P/B Ratio (Annual)1.17x

Inventory Turnover (TTM)1.15x

Pretax Margin (TTM)-2978.85%

Book Value / Share (Annual)$2.17

Price vs S&P 500 (13W)-18.19%

Beta1.24x

Revenue / Share (TTM)$0.00

ROE (TTM)-281.30%

52-Week Low$1.67

vGradeD

mGradeD

vgmGradeD

PCSA Earnings Surprise History

Q4 24-18.50est. -23.00

Q1 25-7.50est. -19.25

Q2 25-6.25est. -5.75

Q3 25-1.75est. -2.00

PCSA Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.14

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
PCSAProcessa Pharmaceuticals, Inc. Common	D	—	D	$2.18
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Processa Pharmaceuticals, Inc. Common

Processa Pharmaceuticals is a clinical-stage biopharmaceutical company developing Next Generation Chemotherapy (NGC) oncology treatments by modifying how the body processes existing FDA-approved cancer drugs while maintaining their mechanism of action. The company's pipeline includes three NGC drug candidates: PCS6422 (NGC-Cap), PCS3117 (NGC-Gem), and PCS11T (NGC-Iri).